Ian Simmons

Lawyer (Partner)

Ian Simmons is a partner in O’Melveny’s Washington, DC office and a member of the Antitrust and Competition Practice. An alumnus of the US Department of Justice, Antitrust Division, Ian has over twenty years of experience in antitrust litigation, with a particular emphasis on cartel class actions and matters involving intellectual property. Ian was named one of Law 360’s “2011 MVPs of the Year—Competition Practice.” Ian has been lead counsel in over 30 multi-district litigation (MDL) antitrust proceedings. He is currently lead counsel for Samsung Electronics Co. Ltd. and Samsung Electronics of America in antitrust actions involving Cathode Ray Tubes and Optical Disk Drives and Lithium Batteries. He also is lead counsel for Asiana Airlines, Inc. in two MDL actions involving direct and indirect purchaser classes of air passengers and air cargo services. He also represents Marriott International in an antitrust MDL involving online travel company booking. Ian has argued before the US Court of Appeals for the Second, Third, Fourth, Seventh and Ninth Circuits and the highest courts in New York and South Dakota and has tried seven cases to verdict.

Distinctions

Auteurs associés

Simpson Thacher & Bartlett (Washington DC)
Ropes & Gray (San Francisco)
Hausfeld (Washington)
United Kingdom’s Competition Authority - CMA (London)
US Court of Appeals for the Seventh Circuit (Chicago)
ESSEC Business School (Cergy)
University of Pennsylvania - The Wharton School of Management (Philadelphia)
Baker Botts (Washington)

Articles

1678 Revue

David Bosco, Ian Simmons, James Killick, Kenneth R. O’Rourke, Ombline Ancelin, Pascal Berghe, Pierre Régibeau, Stephen McIntyre Pay for delay : Les accords de report d’entrée dans le secteur pharmaceutique

1678

Les auteurs de ce Tendances évoquent les décisions rendues aux Etats-Unis et en Europe relatives aux accords de report d’entrée dans le secteur pharmaceutique. Ces accords se sont multiplié ces dernières années et on pour objet de différer dans le temps l’arrivée d’un médicament générique qui pourrait (...)

Envoyer un message